Public market insider buying at Canntab Therapeutics (PILL)

Public market insider buying at Canntab Therapeutics (C:PILL)

Richard Goldstein, CFO, Director and 10% Holder, acquired 310,000 Common Shares on a direct ownership basis at prices ranging from $0.720 to $0.745 between February 7th, 2022 and February 10th, 2022. This represents a $225,950 investment into the company's shares and an account share holdings change of 22.1%.

Canntab Therapeutics is in the Pharmaceuticals Sub Industry Group under the Healthcare Sector.

Canntab Therapeutics Limited is Canada-based biopharmaceutical company. The Company is focused on the manufacturing and distribution of a suite of hard pill cannabinoid formulations in multiple doses and timed-release combinations. The Company operates in one reportable operating, being engaged in the medical marijuana business. All property and equipment, right-of-use assets and intangible assets are located in Canada. Its hard pill cannabinoid formulations provide doctors, patients and consumers with medical grade solutions. Its products include INSTANT RELEASE - (IR Tablet), EXTENDED-RELEASE - (XR Tablet), and ORAL DISSOLVING - O.D. Tablet. It holds cannabis standard processing and sales for medical purposes license, a cannabis research license, and an industrial hemp license from health Canada. Canntab Therapeutics Limited (PILL) has a high amount of executive buying compared to its micro-cap peers in the market over the past three months. According to regulatory filings yesterday, one insider has invested a total amount of $225,950.